Image

Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries (BIO-OSCAR First)

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

The purpose of this study is to evaluate the standard of care practices, procedural outcomes, and in-hospital complications for endovascular peripheral interventions of femoral, popliteal and infrapopliteal lesions.

Description

This is a prospective, multicenter, all-comers observational study. Primary endpoint was procedural success (defined as a combination of successful primary target lesion crossing, residual stenosis of ≤30% following vessel preparation and before definite treatment) and absence of procedural complications (defined as target vessel perforation or rupture, acute occlusion, and distal embolization).

Eligibility

Inclusion Criteria:

  1. Subject ≥18 years old
  2. Subject has provided written informed consent
  3. Subject has Rutherford classification 2 to 6
  4. Reference vessel diameter ≥2 and ≤7 mm
  5. Target lesion(s) has stenosis >70% by visual assessment
  6. Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between will be considered one lesion.

    Above the knee (ATK) group:

  7. Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)
  8. At least one below-knee artery patent to the ankle
  9. Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and result in ≤30% residual stenosis and no evidence of embolization or significant complications.

    Below the knee (BTK) group:

  10. Target lesions involve arteries below the tibial plateau
  11. Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications

Exclusion Criteria:

  1. Subject has a single target lesion that involves both ATK and BTK segments.
  2. Subject not suitable for receiving endovascular procedures of lower limb arteries.
  3. Prior planned major amputation in the target limb (i.e., above the ankle).
  4. Subject with previous bypass surgery of target vessel.
  5. History of any open surgical procedure within the past 30 days.
  6. Planned vascular surgery procedure within the next 30 days after the ATK and/or BTK procedure on the target limb.

    Note: The inflow vessels can be treated on the day of the procedure.

  7. Subject has Oscar IFU listed contraindication (such as uncorrected bleeding disorders, sepsis).
  8. Subject under dialysis.
  9. Subject currently enrolled in another investigational device, biologic, or drug trial in which the primary endpoint has not yet been reached.
  10. Subject lacking capacity to provide informed consent.
  11. Subject under judicial protection, tutorship, or curatorship (for France only).

Study details

Peripheral Arterial Disease, Peripheral Arterial Disease(PAD)

NCT06758921

Biotronik AG

13 January 2025

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.